ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (NCT05671510)
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
🩺 Plain-English Summary (8th-Grade Level)
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once every 21 days, for up to 17 cycles in approximately one year.
Who can join: Review the eligibility criteria below.
Location: XCancer/Dothan Hematology & Oncology - 1114 — Dothan, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (152 Sites)
Showing the first 25 of 152 sites.
- XCancer/Dothan Hematology & Oncology - 1114 — Dothan, Alabama
- Genesis Cancer and Blood Institute - 1123 — Russellville, Arkansas
- The Oncology Institute (TOI) Clinical Research - 1109 — Cerritos, California
- Emad Ibrahim MD Inc. - 1147 — Redlands, California
- UC Davis Comprehensive Cancer Center - 1103 — Sacramento, California
- Bass Medical Group - 1155 — Walnut Creek, California
- Nuvance Health - 1118 — Norwalk, Connecticut
- D&H Cancer Research Center LLC - 1153 — Margate, Florida
- Ocala Oncology Center PL - 1102 — Ocala, Florida
- AdventHealth Cancer Institute - 1105 — Orlando, Florida
- Orlando Health - 1130 — Orlando, Florida
- Florida Cancer Specialists -South - 1126 — Sarasota, Florida
- Florida Cancer Specialists -North - 1125 — The Villages, Florida
- Florida Cancer Specialists -East - 1124 — West Palm Beach, Florida
- Orchard Healthcare Research, Inc. - 1116 — Skokie, Illinois
- Springfield Clinic - The Cancer Center - 1110 — Springfield, Illinois
- Fort Wayne Medical Oncology - 1133 — Fort Wayne, Indiana
- Deaconess Chancellor Center for Oncology - 1131 — Newburgh, Indiana
- Cotton O'Neil Clinical Research Center - 1151 — Topeka, Kansas
- University of Kentucky - Markey Cancer Center - 1112 — Lexington, Kentucky
- Norton Cancer Institute - 1108 — Louisville, Kentucky
- Jefferson City Medical Group - 1145 — Jefferson City, Missouri
- MidAmerica Cancer Care - 1163 — Kansas City, Missouri
- Astera Cancer Care - 1128 — East Brunswick, New Jersey
- Duke University Medical Center - 1158 — Durham, North Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non Small Cell Lung Cancer
- The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance — Boston, Massachusetts
- A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer — Middletown, New Jersey
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC — Beverly Hills, California
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer — Columbus, Georgia
- Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease — Edmonton, Alberta
- A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer — Springdale, Arkansas
Explore by condition: All Non Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.